Theranos Film Revives Scrutiny as Blood-Testing Start-Ups Multiply a Decade After Collapse

3.0 · 8d ago · US · TECH

The Facts

  • The film 'You Can See Everything' chronicles Elizabeth Holmes's final weeks before she went to prison in 2023 and was released in the US last week. Nature only
  • US federal juries ruled that Theranos misled investors about its device's capabilities; two executives, including Holmes, were sentenced to more than a decade in prison. Nature only
  • Theranos, based in Palo Alto, California, claimed its Edison device could run hundreds of tests on a few drops of finger-prick blood; Nature reports it instead diluted patient samples and ran them on other companies' standard machines, in some cases producing skewed measurements. Nature only
  • Babson Diagnostics' BetterWay service uses a specialized device that extracts 6-12 drops of blood from a finger prick and is designed to reduce cell damage, according to founder Eric Olson. Nature only
  • University of Washington bioengineer Paul Yager says the number of blood-testing start-ups has multiplied over the past year, and he attributes the boom largely to wealthy individuals and influencers promoting biomarker tests, many not yet validated. Nature only
Dive deeper · 1 more factShow less
  • Yager says small finger-prick samples can be contaminated by burst blood cells and may barely register low-concentration biomarkers such as HIV viral particles. Nature only

Context

Nature reports that the release of the film 'You Can See Everything' has returned attention to Elizabeth Holmes and Theranos, whose collapse still shapes the diagnostics industry more than a decade later.

Diagnostics developers quoted by Nature say the company's failure made evidence and transparency central, while technical limits of finger-prick testing remain. Some firms are engineering around those limits rather than trying to overcome them.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 0.

3 Informed Citizen This is a feature/commentary piece about a film's release and renewed interest in Theranos and the blood-testing industry, with no new concrete regulatory action, product recall, or policy change affecting ordinary people, so its impact is limited and niche.
3 Business Analyst The story is a feature about a film release and general commentary on the blood-testing industry, with no new concrete market-moving action, regulatory shift, or corporate event beyond a minor startup product description.
3 News Editor The story is a feature about a film release and commentary on a sector trend, with no concrete new event like a regulatory action, major recall, or large-scale impact, so it is minor news with limited immediate effect.

Source

← All stories